This white paper summarizes the HOPA/AMCP forum and serves as a call to action to health system pharmacists to engage in the continuum of cancer care as essential providers of value through the implementation of quality processes that inform safe and effective treatment choices, enhance patient satisfaction with care, and reduce unnecessary healthcare costs. Panel discussions provided examples of successful collaborations between health systems and payers, enabling data exchange and risk stratification of patients and subsequent reorganization of pharmacy resources from volume to value-based activities.
Read my white paper here: Value Of Cancer Care Forum
Overcoming Barriers to Biosimilar Adoption: Real-World Perspectives from a National Payer And Provider Initiative
During this moderated discussion between payers and providers, key strategies identified included education about the evidence from switching studies and real-world evidence from post-marketing studies. Pharmacists in specialty and community settings can play a key role in providing that continuous education.
Increasing transparency about the pricing of and cost savings from biosimilars was equally important, as well as aligning incentives across different stakeholders in the healthcare industry.
Read more by clicking here.
Edgar BS, Cheifetz AS, Helfgott SM, et al. Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative. J Manag Care Spec Pharm. 2021;27(8):1129-35.
Science Notes LLC provided full medical writing support for this viewpoint published in the Journal of Managed Care Pharmacy.
Improving Economic and Quality of Life Burden in Pulmonary Arterial Hypertension: A Review of Clinical Data and Strategies to Slow Progression
This article provides a review of goals of therapy in PAH, determinants of prognosis and levels of patient risk, and additional factors that guide treatment decision making. Recent research in combination therapies has created a paradigm shift in the treatment of PAH and will be reviewed. Additionally, recent updates to the American College of Chest Physicians guidelines will be reviewed along with the updated evidence-based treatment algorithm. Finally, trial data will be evaluated for the recently developed agent selexipag and improved treprostinil delivery formulations that may provide enhanced convenience.
Find this continuing education activity here
Gale, S. The Evolving Treatment Landscape of Pulmonary Arterial Hypertension. Am J Manag Care. 2021;27:S35-S41.
Science Notes LLC provided full medical writing support for this educational manuscript and related test questions.